IRX5 Promoted SREBP1 ‐Mediated de Novo Fatty Acid Synthesis via HMGN4 in Hepatocellular Carcinoma
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70441 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Liying Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Laboratories, the Affiliated Hospital of Guizhou Medical University, Guiyang, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Fatty Acids, Homeodomain Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Science and Technology Foundation of Guizhou province, Doctor Fund from Affiliated Hospital of Guizhou Medical University, Science and Technology Foundation of Guizhou Provincial Health Commission.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC), a prevalent malignant tumour, ranks highly in both morbidity and mortality, and its prevention and treatment need further studies. The transcription factor iroquois homeobox 5 (IRX5) plays an essential role in HCC, whereas little is known about its exact functions and underlying mechanisms in tumour metabolism reprogramming. Besides, as a transcription factor that mainly locates in nuclei, IRX5 lacks a nuclear localisation sequence, which makes uncovering the mechanism of IRX5 translocating into the nuclei of great significance. Here, we first found that both IRX5 and HCC development are highly expressed; IRX5 accelerates de novo fatty acid synthesis and promotes cancer cell proliferation and progression. Moreover, the GST pull‐down combined with GC/MS experiments identified an interaction between IRX5 and high‐mobility group nucleosomal binding domain 4 (HMGN4). Immunofluorescence analysis showed that IRX5 and HMGN4 colocalised within the nucleus. Coimmunoprecipitation further confirmed their direct interaction. The elevated expression of HMGN4 enhanced the nuclear transport of IRX5. Taken together, our observations suggest that HMGN4 driving IRX5 nuclear translocation promotes HCC development via de novo fatty acid synthesis reprogramming.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Clinical Laboratories, the Affiliated Hospital of Guizhou Medical University, Guiyang, People's Republic of China.
- School of Basic Medical Sciences/School of Biology & Engineering, Guiyang, Guizhou, People's Republic of China.
- Guizhou Prenatal Diagnosis Center, the Affiliated Hospital of Guizhou Medical University, Guiyang, People's Republic of China.
- School of Public Health, the key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang, China.
- Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, People's Republic of China.
ORCID-Profile: Changyudong Huang
Förderung
- The Science and Technology Foundation of Guizhou province
- Doctor Fund from Affiliated Hospital of Guizhou Medical University
- Science and Technology Foundation of Guizhou Provincial Health Commission
Zitieren
APA
Zhu, L., Xu, Y., Huang, C., Li, C., Zhang, Y., Li, X., Pan, W., & Zeng, Z. (2025). IRX5 Promoted SREBP1 ‐Mediated de Novo Fatty Acid Synthesis via HMGN4 in Hepatocellular Carcinoma. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70441
Vancouver
Zhu L, Xu Y, Huang C, Li C, Zhang Y, Li X, et al. IRX5 Promoted SREBP1 ‐Mediated de Novo Fatty Acid Synthesis via HMGN4 in Hepatocellular Carcinoma. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70441
BibTeX
@article{Zhu2025,
author = {Zhu, Liying and Xu, Yongjie and Huang, Changyudong and Li, Chengcheng and Zhang, Yiqiong and Li, Xing and Pan, Wei and Zeng, Zhu},
title = {IRX5 Promoted SREBP1 ‐Mediated de Novo Fatty Acid Synthesis via HMGN4 in Hepatocellular Carcinoma},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70441}
}
EUVIMED